IP Library › Granted Patent US 11,180,551
Granted Patent B2
US 11,180,551 · App. 16/851,420 · Granted Nov 23, 2021

Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)

Inventors: Kevin Peters (Cincinnati, OH); Michael Allen Flynn (Ann Arbor, MI)
Assignee: EyePoint Pharmaceuticals, Inc.
C07K16/28A61K39/3955C07K16/22C07K16/2896A61K2039/505A61K2039/507A61K2039/54A61K2039/545C07K2317/24C07K2317/33C07K2317/51C07K2317/515C07K2317/75C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,180,551
App. No.
16/851,420
Granted
Nov 23, 2021
Kind
B2
Abstract

The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.

Claims (41)

1. An antibody comprising:

a light chain variable domain sequence that is any one of SEQ ID NOs: 20-23,

wherein the light chain variable domain sequence comprises complementarity-determining region (CDR) sequences that are SEQ ID NO: 57, SEQ ID NO: 58, and SEQ ID NO: 59,

wherein the light chain variable domain sequence is contained within a light chain sequence that is any one of SEQ ID NOs: 34-37.

2. The antibody of claim 1 , wherein the antibody binds human protein tyrosine phosphatase-beta (HPTP-β).

3. The antibody of claim 1 , wherein the antibody binds an extracellular domain of HPTP-β.

4. The antibody of claim 1 , wherein a binding affinity (K D ) of the antibody to the extracellular domain of HPTP-β is about 70 pM to about 70 nM.

5. The antibody of claim 1 , wherein the antibody binds a first FN3 repeat of an extracellular domain of HPTP-β.

6. The antibody of claim 1 , wherein the antibody inhibits HPTP-β.

7. The antibody of claim 1 , wherein the antibody activates tyrosine kinase with immunoglobulin and epidermal growth factor homology domains 2 (Tie-2).

8. The antibody of claim 1 , wherein the antibody activates Protein kinase B (Akt).

9. The antibody of claim 1 , wherein the antibody is humanized.

10. The antibody of claim 1 , wherein the light chain variable domain sequence is SEQ ID NO: 20.

11. The antibody of claim 1 , wherein the light chain variable domain sequence is SEQ ID NO: 21.

12. The antibody of claim 1 , wherein the light chain variable domain sequence is SEQ ID NO: 22.

13. The antibody of claim 1 , wherein the light chain variable domain sequence is SEQ ID NO: 23.

14. The antibody of claim 1 , wherein the light chain sequence is SEQ ID NO: 34.

15. The antibody of claim 1 , wherein the light chain sequence is SEQ ID NO: 35.

16. The antibody of claim 1 , wherein the light chain sequence is SEQ ID NO: 36.

17. The antibody of claim 1 , wherein the light chain sequence is SEQ ID NO: 37.

18. A pharmaceutical composition comprising a therapeutically effective amount of an antibody comprising:

a light chain variable domain sequence that is any one of SEQ ID NOs: 20-23,

wherein the light chain variable domain sequence comprises complementarity-determining region (CDR) sequences that are SEQ ID NO: 57, SEQ ID NO: 58, and SEQ ID NO: 59,

wherein the light chain variable domain sequence is contained within a light chain sequence that is any one of SEQ ID NOs: 34-37; and

a pharmaceutically acceptable carrier.

19. The composition of claim 18 , wherein the therapeutically effective amount of the antibody is from about 0.25 mg to about 200 mg.

20. The composition of claim 18 , wherein the therapeutically effective amount of the antibody is from about 1 mg/kg to about 10 mg/kg.

21. The composition of claim 18 , wherein the therapeutically effective amount of the antibody is from about 1 mg to about 50 mg.

22. The composition of claim 18 , wherein the therapeutically effective amount of the antibody is from about 50 mg to about 200 mg.

23. The composition of claim 18 , wherein the composition is formulated for intravitreal administration.

24. The composition of claim 18 , wherein the composition is formulated for intravenous administration.

25. The composition of claim 18 , wherein the composition is formulated for subcutaneous administration.

26. The composition of claim 18 , wherein the composition is formulated for topical administration.

27. The composition of claim 18 , wherein the light chain variable domain sequence is SEQ ID NO: 20.

28. The composition of claim 18 , wherein the light chain variable domain sequence is SEQ ID NO: 21.

29. The composition of claim 18 , wherein the light chain variable domain sequence is SEQ ID NO: 22.

30. The composition of claim 18 , wherein the light chain variable domain sequence is SEQ ID NO: 23.

31. The composition of claim 18 , wherein the light chain sequence is SEQ ID NO: 34.

32. The composition of claim 18 , wherein the light chain sequence is SEQ ID NO: 35.

33. The composition of claim 18 , wherein the light chain sequence is SEQ ID NO: 36.

34. The composition of claim 18 , wherein the light chain sequence is SEQ ID NO: 37.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2021
From: AERPIO PHARMACEUTICALS, INC.
To: EYEPOINT PHARMACEUTICALS, INC.
Reel/Frame 057448/0033 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2020
From: PETERS, KEVIN; FLYNN, MICHAEL ALLEN
To: AERPIO PHARMACEUTICALS, INC.
Reel/Frame 052776/0626 →